Pfizer Inc. (NYSE:PFE) Shares Sold by Harbor Advisory Corp MA

Harbor Advisory Corp MA reduced its position in Pfizer Inc. (NYSE:PFE) by 19.3% in the 4th quarter, HoldingsChannel.com reports. The firm owned 101,855 shares of the biopharmaceutical company’s stock after selling 24,417 shares during the quarter. Harbor Advisory Corp MA’s holdings in Pfizer were worth $2,702,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in PFE. Exchange Traded Concepts LLC lifted its stake in shares of Pfizer by 117.0% in the 3rd quarter. Exchange Traded Concepts LLC now owns 69,178 shares of the biopharmaceutical company’s stock valued at $2,002,000 after purchasing an additional 37,293 shares during the period. Thurston Springer Miller Herd & Titak Inc. raised its position in Pfizer by 28.8% during the third quarter. Thurston Springer Miller Herd & Titak Inc. now owns 23,274 shares of the biopharmaceutical company’s stock worth $674,000 after acquiring an additional 5,205 shares during the period. ORG Wealth Partners LLC acquired a new position in Pfizer during the third quarter worth $115,000. Fiduciary Alliance LLC raised its position in Pfizer by 15.5% during the third quarter. Fiduciary Alliance LLC now owns 8,484 shares of the biopharmaceutical company’s stock worth $246,000 after acquiring an additional 1,140 shares during the period. Finally, CX Institutional raised its position in Pfizer by 80.1% during the third quarter. CX Institutional now owns 46,207 shares of the biopharmaceutical company’s stock worth $1,337,000 after acquiring an additional 20,552 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Trading Down 1.3 %

Shares of PFE opened at $25.53 on Wednesday. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54. The firm has a 50-day moving average price of $26.28 and a 200 day moving average price of $27.69. The firm has a market capitalization of $144.69 billion, a P/E ratio of 18.11, a P/E/G ratio of 0.64 and a beta of 0.64.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. During the same quarter in the prior year, the firm posted $0.10 earnings per share. Pfizer’s quarterly revenue was up 24.7% on a year-over-year basis. Sell-side analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.74%. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio is currently 121.99%.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the stock. Guggenheim restated a “buy” rating and set a $33.00 price objective on shares of Pfizer in a research report on Monday. Citigroup reduced their price objective on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. Truist Financial reduced their price objective on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. Wolfe Research initiated coverage on shares of Pfizer in a research report on Friday, November 15th. They set an “underperform” rating and a $25.00 price objective for the company. Finally, Sanford C. Bernstein initiated coverage on shares of Pfizer in a report on Thursday, October 17th. They set a “market perform” rating and a $32.00 target price for the company. One analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, Pfizer currently has a consensus rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.